- The research, spanning quantitative ultrasound imaging to AI-driven clinical solutions, aims to enhance liver disease management by improving patient care pathways and outcomes
- Our collaboration with Siemens Healthineers is a transformative step in using AI to redefine non-invasive diagnostics for liver disease: Sangita Reddy, Joint Managing Director – Apollo Hospitals
- Our joint effort will help address the unmet needs in liver disease diagnosis and treatment, and we look forward to a fruitful partnership: Hariharan Subramanian, Managing Director, Siemens Healthcare, Private Limited.
NE HEALTH BUREAU
AHMEDABAD, JULY 23
Apollo Hospitals and Siemens Healthineers on Wednesday announced a research collaboration founded on a shared ambition to advance innovations in artificial intelligence (AI) and imaging technologies, with the goal of improving lives. The research, spanning quantitative ultrasound imaging to AI-driven clinical solutions, aims to enhance liver disease management by improving patient care pathways and outcomes—from early detection and risk stratification to monitoring intervention and therapy response.
The partnership combines technical and clinical expertise to develop innovative healthcare solutions for the growing burden of liver diseases in India, focusing on early diagnosis, accurate detection, and precise monitoring to improve patient outcomes.
As per Government of India guidelines, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), referred to as NAFLD in the report, is a growing cause of liver disease in India. Prevalence ranges from 9% to 32%, higher among those who are overweight, obese, or have diabetes. NFHS-4 (2015-2016) reports 18-20% of adults are overweight/obese and 3-8% have abnormal blood sugar. MASLD significantly increases cardiovascular risk, with heart disease being the leading cause of death.
Dr. Sangita Reddy, Joint Managing Director – Apollo Hospitals said, “At Apollo, we believe that the future of healthcare lies at the intersection of clinical excellence and cutting-edge technology anchored in patient centricity. Our collaboration with Siemens Healthineers is a transformative step in using AI to redefine non-invasive diagnostics for liver disease. Due to diagnostic challenges and the evolving understanding of the disease, the true prevalence of MASLD may be underestimated that poses a significant public health challenge, requiring increased awareness, early detection, and effective management strategies. AI-driven disease progression models shall play a pivotal role in early detection of fibrosis, allowing timely interventions, cost-effective screening, and improved patient outcomes. This model shall also facilitate precision population health strategies and clinical decision support across care settings. This partnership also reflects Apollo’s pioneering vision to embed intelligent systems across the clinical spectrum that predict faster, more accurate diagnoses and proactive patient management.”
“Liver disease is a growing health concern in India; it’s crucial to prioritize early diagnosis and prevention through advanced diagnostic tools, lifestyle changes, and increased awareness to reverse this trend. We believe that advanced technologies will aid timely and precise diagnosis, leading to better disease management and improving the quality of life for patients. Our joint effort will help address the unmet needs in liver disease diagnosis and treatment, and we look forward to a fruitful partnership,” said Hariharan Subramanian, Managing Director, Siemens Healthcare, Private Limited.
Following the 2024 Memorandum of Understanding, the Master Research Agreement (MRA) was formalized in March 2025, establishing a foundation for collaborative research in diagnostic and interventional ultrasound imaging. The signing ceremony for the Master Research Agreement Addendum was held on Wednesday, in Hyderabad, marking a significant milestone in this partnership.
